Cygna Labs Expands DNS Cloud Integration in Latest IPControl Release

MIAMI, Fla., January 21, 2025 — Cygna Labs, a highly specialized software developer and a leading provider of DDI, cloud security, and compliance technology solutions, announced today its newest release of IPControl software, version 16.0, with several new cloud, security, and usability features for Cygna DDI customers.

Key new features in IPControl 16.0 include cloud DNS integration with Amazon Route 53, Azure DNS and Googe DNS cloud services. Customers may view, add, modify, and delete DNS zones and resource records in these cloud systems, in addition to leveraging cloud DNS proxy host support. Other key IPControl features include support for the Cygna Labs QDHCP server, OAuth2 authentication, streamlined appliance provisioning, expanded automation capabilities including a new Python SDK, and several usability and security improvements.

“Many customers depend on cloud for their mission-critical enterprise applications, which in turn rely on DNS for connecting end users,” stated Christian Ehrenthal, president and CEO, Cygna Labs Corp. “Cygna DDI solutions offer full visibility and control into market-leading cloud DNS services in addition to premises-based servers, providing a single holistic management interface for customers’ multi-vendor, multi-platform DHCP and DNS servers.”

“Our QDHCP server is the industry’s fastest and most reliable DHCP server,” added Michael Dooley, SVP DDI, Cygna Labs Corp. “Cygna DDI offers centralized management of customers’ diverse DHCP deployments, including stock ISC DHCP, Kea, and Microsoft DHCP, as well as our own QDHCP server.”

About Cygna Labs Cygna Labs is a software developer and one of the top three global DDI vendors. Many Fortune 100 customers rely on Cygna Labs’ DDI products and services, in addition to its industry-leading security and compliance solutions, to detect and proactively mitigate data security threats, affordably pass compliance audits, and increase the productivity of their IT departments. For more information, visit https://cygnalabs.com.